https://scholars.lib.ntu.edu.tw/handle/123456789/638408
標題: | Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B | 作者: | Lim, Young-Suk Chan, Henry L Y Ahn, Sang Hoon Seto, Wai Kay Ning, Qin Agarwal, Kosh Janssen, Harry L A Pan, Calvin Q Chuang, Wan Long Izumi, Namiki Fung, Scott Shalimar, null Brunetto, Maurizia Hui, Aric Josun Chang, Ting-Tsung Lim, Seng Gee Abramov, Frida Flaherty, John F Wang, Hongyuan Yee, Leland J JIA-HORNG KAO Gane, Edward Hou, Jinlin Buti, Maria |
關鍵字: | REACH-B; aMAP; antiviral therapy; incidence; mPAGE-B | 公開日期: | 十月-2023 | 卷: | 5 | 期: | 10 | 來源出版物: | JHEP reports : innovation in hepatology | 摘要: | Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638408 | ISSN: | 25895559 | DOI: | 10.1016/j.jhepr.2023.100847 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。